We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy

By LabMedica International staff writers
Posted on 13 Jun 2024
Print article
Image: Diff-Quik stained smear from lung FNAB (Photo courtesy of Guoping Cai, Darin Dolezal, Ivana Kholová)
Image: Diff-Quik stained smear from lung FNAB (Photo courtesy of Guoping Cai, Darin Dolezal, Ivana Kholová)

Lung cancer continues to be the most common cause of cancer-related deaths worldwide and ranks as the second most frequently diagnosed cancer in both men and women. The role of lung cytopathology, which involves examining specimens such as sputum, bronchial brushings (BB), bronchial washings (BW), bronchoalveolar lavage (BAL), and fine needle aspiration biopsy (FNAB), is crucial for early and accurate diagnosis, thus enhancing treatment efficacy. The introduction of endobronchial ultrasound (EBUS) has significantly improved the diagnostic capabilities of FNAB by facilitating simultaneous diagnosis and staging. With the increasing significance of accurate lung tumor classification for molecular testing, there is a crucial need for the implementation of standardized terminology and reporting standards in lung cytopathology.

The World Health Organization (WHO, Geneva, Switzerland) has introduced a new reporting system designed to standardize this communication to enhance diagnostic accuracy, facilitate research, and encourage clinical trial participation. This system, the WHO Reporting System for Lung Cytopathology, developed in collaboration with the International Academy of Cytology (IAC, Freiburg im Breisgau, Germany) and the International Agency for Research on Cancer (IARC, Lyon, France), is the first of its kind aimed at standardizing the reporting of lung cytopathology specimens globally. It categorizes findings into five diagnostic categories—Insufficient/Inadequate/Non-diagnostic, Benign/Negative for Malignancy, Atypical, Suspicious for Malignancy, and Malignant. Each category is defined by specific cytomorphologic criteria, includes an estimated risk of malignancy (ROM), and offers guidelines for clinical management.

The WHO system provides specific clinical management recommendations for each diagnostic category. For instance, a diagnosis of "Malignant" often triggers further diagnostic actions such as bronchoscopy or imaging, possibly followed by EBUS- or CT-guided FNAB. Treatment may vary from surgical resection to systemic treatment, depending on the tumor's characteristics and condition of the patient. For benign results, ongoing monitoring and follow-up are generally recommended, while atypical or suspicious results may require additional testing to refine the diagnosis. The system also highlights the importance of ancillary tests like molecular and genetic testing, crucial for precise diagnoses and personalized treatment plans. These ancillary tests, including immunohistochemistry (IHC) and molecular assays, are critical for confirming diagnoses and are pivotal for identifying targeted therapies, particularly for lung adenocarcinoma and other specific cancer subtypes.

The WHO Reporting System for Lung Cytopathology is a pivotal step in achieving standardized, accurate, and effective lung cancer diagnostics. By providing distinct categories and criteria, it not only improves diagnostic consistency and patient management but also promotes ongoing research. The inclusion of ancillary testing and consideration for resource variability across different settings ensures that the system is applicable worldwide. Additionally, this standardization aids in gathering robust data for epidemiological studies and clinical trials, crucial for progressing our understanding and treatment of lung cancer. As this system becomes more widely adopted, it is expected to markedly enhance outcomes for lung cancer patients and contribute significantly to the global fight against this prevalent disease. Further refinement and research will continue to improve its clinical value and impact, maintaining its relevance in the field of lung cancer diagnostics.

Related Links:
WHO
IAC
IARC

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.